IGC Pharma, Inc. Common Stock (NY:IGC)

0.3010 UNCHANGED

Streaming Delayed Price Updated: 8:00 PM EDT, Apr 9, 2026 Add to My Watchlist

Price and Volume

Volume	6,152
Open	0.3010
Bid (Size)	0.3000 (9,800)
Ask (Size)	0.3187 (500)
Prev. Close	0.3010
Today's Range	0.3010 - 0.3010
52wk Range	0.2420 - 0.4985
Shares Outstanding	49,784,017
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

April 07, 2026

Via ACCESS Newswire

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

March 30, 2026

Via ACCESS Newswire

Performance

YTD	+3.4%	+3.4%
1 Month	+5.6%	+5.6%
3 Month	-1.3%	-1.3%
6 Month	-28.0%	-28.0%
1 Year	+8.7%	+8.7%

More News

New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)

March 28, 2026

Via ACCESS Newswire

New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning

March 25, 2026

Via ACCESS Newswire

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

March 19, 2026

Via ACCESS Newswire

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

March 18, 2026

Via ACCESS Newswire

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

February 26, 2026

Via ACCESS Newswire

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

February 24, 2026

Via ACCESS Newswire

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

February 23, 2026

Via ACCESS Newswire

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

February 17, 2026

Via ACCESS Newswire

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

February 12, 2026

Via ACCESS Newswire

IGC Pharma Announces Equity Research Update by Alliance Global Partners

February 10, 2026

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

February 09, 2026

Via ACCESS Newswire

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

February 02, 2026

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

January 22, 2026

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

January 12, 2026

Via ACCESS Newswire

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

January 06, 2026

Via ACCESS Newswire

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

January 05, 2026

Via ACCESS Newswire

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

December 19, 2025

Via ACCESS Newswire

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

December 15, 2025

Via ACCESS Newswire

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."

December 10, 2025

Via ACCESS Newswire

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

December 09, 2025

Via ACCESS Newswire

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

December 02, 2025

Via ACCESS Newswire

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

November 25, 2025

Via ACCESS Newswire

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

November 17, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is IGC Pharma, Inc. Common Stock publicly traded?

Yes, IGC Pharma, Inc. Common Stock is publicly traded.

What exchange does IGC Pharma, Inc. Common Stock trade on?

IGC Pharma, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for IGC Pharma, Inc. Common Stock?

The ticker symbol for IGC Pharma, Inc. Common Stock is IGC on the New York Stock Exchange

What is the current price of IGC Pharma, Inc. Common Stock?

The current price of IGC Pharma, Inc. Common Stock is 0.3010

When was IGC Pharma, Inc. Common Stock last traded?

The last trade of IGC Pharma, Inc. Common Stock was at 04/09/26 08:00 PM ET

What is the market capitalization of IGC Pharma, Inc. Common Stock?

The market capitalization of IGC Pharma, Inc. Common Stock is 14.98M

How many shares of IGC Pharma, Inc. Common Stock are outstanding?

IGC Pharma, Inc. Common Stock has 15M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.